
样式: 排序: IF: - GO 导出 标记为已读
-
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-27 Chaoyi Zhang, Jin Xu, Rong Tang, Jianhui Yang, Wei Wang, Xianjun Yu, Si Shi
Research into the potential benefits of artificial intelligence for comprehending the intricate biology of cancer has grown as a result of the widespread use of deep learning and machine learning in the healthcare sector and the availability of highly specialized cancer datasets. Here, we review new artificial intelligence approaches and how they are being used in oncology. We describe how artificial
-
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-22 Long Chen, Anqi Ren, Yuan Zhao, Hangyu Chen, Qifang Wu, Mengzhu Zheng, Zijian Zhang, Tongcun Zhang, Wu Zhong, Jian Lin, Haichuan Zhu
T-cell acute lymphoblastic leukemia (T-ALL) is a type of hematologic tumor with malignant proliferation of hematopoietic progenitor cells. However, traditional clinical treatment of T-ALL included chemotherapy and stem cell transplantation always lead to recurrence and poor prognosis, thus new therapeutic targets and drugs are urgently needed for T-ALL treatment. In this study, we showed that TET1
-
Genitourinary cancers updates: highlights from ASCO 2023 J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-21 Qian Qin, Hollie Sheffield, Sean M. Taasan, Andrew Z. Wang, Tian Zhang
Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors
-
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-09 Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma
Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performed a multicenter retrospective cohort study to evaluate the outcomes of patients with secondary CNS lymphoma (SCNSL) who received CAR-T. Eligibility required active
-
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-04 Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Correction: Journal of Hematology & Oncology (2020) 13:2 https://doi.org/10.1186/s13045-019-0840-4 The original article [1] contains an erroneous bottom-right panel of Fig. 6F. The corrected sub-figure can be viewed ahead in this Correction article. Fig. 6 AGK stimulates the PI3K/AKT signalling pathway. a KEGG analysis was conducted to identify the pathways activated by AGK overexpression in RCC. b
-
Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-01 Zengyu Feng, Kexian Li, Kai Qin, Juyong Liang, Minmin Shi, Yang Ma, Shiwei Zhao, Huaiyu Liang, Dongni Han, Baiyong Shen, Chenghong Peng, Hao Chen, Lingxi Jiang
Retraction to: Journal of Hematology & Oncology (2022) 15:112 https://doi.org/10.1186/s13045-022-01338-9 The Editor-in-Chief has retracted this article because of significant concerns regarding a number of Figures presented in this work, which question the integrity of the data. The Editor-in-Chief therefore no longer has confidence in the integrity of the data in this article. Lingxi Jiang does not
-
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-10-25 Yannick Bulliard, Borje S. Andersson, Mehmet A. Baysal, Jason Damiano, Apostolia M. Tsimberidou
T cell differentiation is a highly regulated, multi-step process necessary for the progressive establishment of effector functions, immunological memory, and long-term control of pathogens. In response to strong stimulation, as seen in severe or chronic infections or cancer, T cells acquire a state of hypo-responsiveness known as exhaustion, limiting their effector function. Recent advances in autologous
-
CRISPR screening in hematology research: from bulk to single-cell level J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-10-24 Sarah Meyers, Sofie Demeyer, Jan Cools
The CRISPR genome editing technology has revolutionized the way gene function is studied. Genome editing can be achieved in single genes or for thousands of genes simultaneously in sensitive genetic screens. While conventional genetic screens are limited to bulk measurements of cell behavior, recent developments in single-cell technologies make it possible to combine CRISPR screening with single-cell
-
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-29 Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Correction : Journal of Hematology & Oncology (2023) 16:58 https://doi.org/10.1186/s13045-023-01450-4 The original article [1] incorrectly presents Affiliation 7. The correct affiliation can be viewed ahead in this Correction article: 7Transplantation Unit Department of Oncology and Haematology, IRCCS Humanitas Research Hospital, Milan, Italy. Nagler A, et al. Non-T-depleted haploidentical transplantation
-
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-29 Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yangqiu Li
Correction to: Cai et al. Journal of Hematology & Oncology (2023) 16:101 https://doi.org/10.1186/s13045-023-01499-1 The original article [1] contained an error mistakenly introduced by the production team whereby co-first authorship for the first three co-authors was omitted. This has since been restored accordingly. Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
-
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-14 Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke van den Berg, Marcel Nijland
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic
-
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-12 Hao-Ran Jin, Jin Wang, Zi-Jing Wang, Ming-Jia Xi, Bi-Han Xia, Kai Deng, Jin-Lin Yang
Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and survive in unfavorable environments that lack oxygen and nutrients, tumor cells undergo metabolic transformations to exploit various ways of acquiring lipid and increasing lipid oxidation. In addition, stromal cells and immune cells in the tumor microenvironment also undergo lipid metabolic
-
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-09 Changsong Qi, Tong Xie, Jun Zhou, Xicheng Wang, Jifang Gong, Xiaotian Zhang, Jian Li, Jiajia Yuan, Chang Liu, Lin Shen
Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT04581473 and NCT03874897). In case 1, with CLDN 18.2 expression of 2+, 70%, 250 × 106 cells were infused after lymphodepletion. Grade 1 cytokine release syndrome (CRS) occurred on d1 which was later
-
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-05 Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yangqiu Li
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies. Thus, an increasing number of immune checkpoint proteins (ICPs) have been screened
-
Recent advances in targeted strategies for triple-negative breast cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-28 Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple
-
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-25 Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors (BTKi). BTKi has shown excellent outcomes for patients with relapsed or refractory MCL and is now being studied in
-
Advances in single-cell RNA sequencing and its applications in cancer research J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-24 Dezhi Huang, Naya Ma, Xinlei Li, Yang Gou, Yishuo Duan, Bangdong Liu, Jing Xia, Xianlan Zhao, Xiaoqi Wang, Qiong Li, Jun Rao, Xi Zhang
Cancers are a group of heterogeneous diseases characterized by the acquisition of functional capabilities during the transition from a normal to a neoplastic state. Powerful experimental and computational tools can be applied to elucidate the mechanisms of occurrence, progression, metastasis, and drug resistance; however, challenges remain. Bulk RNA sequencing techniques only reflect the average gene
-
Challenges and new technologies in adoptive cell therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-18 Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and chimeric antigen receptor (CAR)-T cell therapies, many novel strategies for cancer treatment have been developed. Owing to its promising outcomes, CAR-T cell therapy has revolutionized the field of ACTs, particularly for
-
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-17 Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel, Sabine Kayser, Konstanze Döhner, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Jannik Labrenz, Dominic Edelmann, Melanie Märklin, Wichard Vogel, Wolfgang Bethge, Juliane S. Walz, Ludger Große-Hovest, Martin Steiner, Gundram Jung, Helmut R. Salih
About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, which is abundantly expressed on AML cells. This first-in-human, open-label, single-arm, multicenter trial included AML patients in CR with persisting or increasing MRD and evaluated safety/tolerability
-
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-15 Huajie Song, Dan Li, Xiaojing Wang, Erhu Fang, Feng Yang, Anpei Hu, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Kai Huang, Liduan Zheng, Qiangsong Tong
Retraction Note: Journal of Hematology & Oncology (2020) 13:24 https://doi.org/10.1186/s13045-020-00857-7 The Editor-in-Chief has retracted this article. After publication, concerns were raised about image reuse in the article. Specifically: The top-left panel of Fig. 2F was reproduced in two panels of Fig. 4H, and in Fig. S11E of the supplementary materials. There is overlap between the top-left panel
-
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-12 Mengke Niu, Ming Yi, Yuze Wu, Lijuan Lyu, Qing He, Rui Yang, Liang Zeng, Jian Shi, Jing Zhang, Pengfei Zhou, Tingting Zhang, Qi Mei, Qian Chu, Kongming Wu
Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not sufficient to restore normal immune response. Other negative regulators of antitumor immunity, like TGF-β and VEGFA, are also involved in immune escape of tumor cells and induce immunotherapy resistance
-
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-08 Matthieu Roulleaux-Dugage, Antoine Italiano
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology
-
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-03 Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo, Yongping Song
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment
-
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-03 Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D. Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K. Balasubramanian, Hussein Awada, Ramsha Ahmed, Minako Mori, Manja Meggendorfer, Torsten Haferlach, Valeria Visconte, Jaroslaw P. Maciejewski
TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly leukemogenic, questioning the presence of cryptic biallelic subclones in cases with dismal prognosis. We have collected clinical and molecular data of 7400 patients with myeloid neoplasms and
-
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-03 Xinyuan Liu, Juanjuan Zhao, Xiangqian Guo, Yongping Song
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20+ NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on
-
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-02 Ya-Nan Qi, Zhu Liu, Lian-Lian Hong, Pei Li, Zhi-Qiang Ling
RNA modification has recently become a significant process of gene regulation, and the methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification, methylating various types of RNAs, including mRNA, tRNA, microRNA, rRNA, and mitochondrial RNAs. METTL proteins consist of a unique seven-beta-strand domain, which binds to the methyl donor SAM to catalyze methyl transfer
-
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-31 Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound and prolonged cytopenias) represents the most common grade ≥ 3 toxicity and can predispose for severe infectious complications. Here, we examined
-
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-31 Dong-Jun Fu, Ting Wang
NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulation of diverse biological processes. NEDD8-activating enzyme (NAE) as the only activation enzyme in the NEDDylation modification has become an attractive target to develop anticancer drugs. To date, numerous inhibitors or agonists targeting NAE have been developed. Among them, covalent
-
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-28 James F. Wu, Binod Dhakal
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two approved BCMA-targeted CAR-T cell therapies, investigators globally are working to build off and improve
-
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-28 Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li, Xiaonan Chen
Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical
-
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-27 Wenjing Lei, Zhuoliang Liu, Zhiyuan Su, Panpan Meng, Chun Zhou, Xiaomei Chen, Zheng Hu, An Xiao, Miaomiao Zhou, Liping Huang, Yiyue Zhang, Xianhui Qin, Junping Wang, Fengxin Zhu, Jing Nie
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the influence of HHcy on thrombopoiesis remains largely unknown. Here, we reported increased platelet count (PLT) in mice and zebrafish with HHcy. In hypertensive patients (n = 11,189), higher serum level
-
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-27 Antonio Tapia-Galisteo, Luis Álvarez-Vallina, Laura Sanz
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recruitment of T cells and CD16a for NK cells. The first T cell engager (the anti-CD19 blinatumomab) was approved by the FDA in 2014, but no other one hit the market until 2022. Now the field is gaining
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-27 Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu, John Mascarenhas
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival versus the general population and often experience burdensome signs and symptoms that reduce quality of life. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was initially approved by the
-
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-25 N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jiménez-Ubieto, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz, J. Martinez-Lopez
Correction : Journal of Hematology & Oncology (2023) 16:76 https://doi.org/10.1186/s13045-023-01474-w The original article [1] mistakenly truncated co-author, A. Jiménez-Ubieto’s name which has since been amended. Lopez-Muñoz N, et al. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma. J Hematol Oncol. 2023;16:76. Article PubMed PubMed Central Google Scholar Download
-
Metabolism, metabolites, and macrophages in cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-25 Mengyuan Li, Yuhan Yang, Liting Xiong, Ping Jiang, Junjie Wang, Chunxiao Li
Tumour-associated macrophages (TAMs) are crucial components of the tumour microenvironment and play a significant role in tumour development and drug resistance by creating an immunosuppressive microenvironment. Macrophages are essential components of both the innate and adaptive immune systems and contribute to pathogen resistance and the regulation of organism homeostasis. Macrophage function and
-
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-22 Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas Kulozik, Joachim Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper
Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL). Thirteen patients were treated with escalating doses
-
Novel target and treatment agents for natural killer/T-cell lymphoma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-22 Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the treatment. Specifically, the use of asparaginase-containing regimens has led to substantial improvement in survival outcomes in NKTCL patients. Novel treatment strategies that are currently under
-
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-20 Jiawei Fan, Ye Yu, Lanzhen Yan, Yuncang Yuan, Bin Sun, Dong Yang, Nan Liu, Jing Guo, Jie Zhang, Xudong Zhao
The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells and tumor-associated macrophages and promote the development of cancers including pancreatic tumor. Targeting TAM receptors could be a promising therapeutic option. We designed a novel CAR based on the extracellular domain of growth arrest-specific protein 6 (GAS6), a natural ligand
-
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-19 N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jimenez, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz, J. Martinez-Lopez
Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evolution of the survival of patients with MM in three groups based on age at MM diagnosis over three time periods between 1999 and 2020 at our 12 de Octubre Hospital institution (H12O). Then, to confirm our results, we used data from TriNetx, a global health research platform that
-
Clinical development of mRNA therapies against solid tumors J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-18 Dawei Wu, Lingfeng Hu, Xin Wang, Yue Yu, Shuo-Peng Jia, Hui-Yao Huang, Zi-Wei Li, Jin-Feng Ma, Hai-Bo Zhu, Yu Tang, Ning Li
The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove database, a total of 108 clinical trials from 1999 to 2021 were retrospectively analyzed. We have demonstrated
-
Advances of medical nanorobots for future cancer treatments J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-14 Xiangyi Kong, Peng Gao, Jing Wang, Yi Fang, Kuo Chu Hwang
Early detection and diagnosis of many cancers is very challenging. Late stage detection of a cancer always leads to high mortality rates. It is imperative to develop novel and more sensitive and effective diagnosis and therapeutic methods for cancer treatments. The development of new cancer treatments has become a crucial aspect of medical advancements. Nanobots, as one of the most promising applications
-
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-08 Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero
Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax. This single-center, phase 1/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed
-
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-08 Rory Bennett, Mary Ann Anderson, John F. Seymour
The treatment landscape for chronic lymphocytic leukemia (CLL) continues to undergo considerable evolution. Optimal selection of initial therapy from multiple effective options provides a major challenge for clinicians, who need to consider both disease and patient factors in conjunction with a view to sequencing available therapies in event of disease relapse. We explore the most topical clinically
-
Tumor-associated myeloid cells in cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-06 Xinyu Cheng, Huilan Wang, Zhongyu Wang, Bo Zhu, Haixia Long
Tumor-associated myeloid cells (TAMCs) are among the most important immune cell populations in the tumor microenvironment, and play a significant role on the efficacy of immune checkpoint blockade. Understanding the origin of TAMCs was found to be the essential to determining their functional heterogeneity and, developing cancer immunotherapy strategies. While myeloid-biased differentiation in the
-
A gene signature can predict risk of MGUS progressing to multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-29 Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Siegfried Janz, Bart Barlogie, Frits Van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting MGUS progression has not been produced. We have explored the use of gene expression profiling to risk-stratify MGUS and developed an optimized signature based on large samples with long-term
-
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-28 Yang Cao, Emanuela C. Marcucci, Lihua E. Budde
Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R/R) follicular lymphoma. The approval was based on results from an international
-
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-26 Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, Alessia Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino, Mariangela Lopreiato, Fredrik Thunarf, Onofrio Cuomo, Maria Cristina Zito, Maria Rosanna De Fina, Amelia Brescia, Simona Gualtieri, Caterina Riillo, Francesco Manti, Daniele Caracciolo, Vito Barbieri, Eugenio
We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity against human xenografts in mice, and favorable toxicokinetics in rats and monkeys. Allometric interspecies scaling allowed us to define the first-in-class LNA-i-miR-221 safe starting dose for the
-
Exosomal circRNA: emerging insights into cancer progression and clinical application potential J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-26 Fan Zhang, Jiajia Jiang, Hui Qian, Yongmin Yan, Wenrong Xu
Exosomal circRNA serves a novel genetic information molecule, facilitating communication between tumor cells and microenvironmental cells, such as immune cells, fibroblasts, and other components, thereby regulating critical aspects of cancer progression including immune escape, tumor angiogenesis, metabolism, drug resistance, proliferation and metastasis. Interestingly, microenvironment cells have
-
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-24 Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence in most patients. Current treatment options are limited, with no therapies specifically approved as third-line or beyond. Delta-like ligand 3 (DLL3), a Notch inhibitory ligand, is an attractive
-
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-23 Jinxin Li, Qiwei Wang, Yingli Han, Lingli Jiang, Siqi Lu, Beini Wang, Wenchang Qian, Meng Zhu, He Huang, Pengxu Qian
Hematologic malignancies (HMs) pose a serious threat to patients’ health and life, and the five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis and the complex clinical symptoms brings immense challenges to the diagnosis and treatment of HMs. Traditional therapeutic strategies for HMs include radiotherapy, chemotherapy, targeted therapy and hematopoietic stem
-
Small RNA modifications: regulatory molecules and potential applications J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-22 Qunli Xiong, Yaguang Zhang
Small RNAs (also referred to as small noncoding RNAs, sncRNA) are defined as polymeric ribonucleic acid molecules that are less than 200 nucleotides in length and serve a variety of essential functions within cells. Small RNA species include microRNA (miRNA), PIWI-interacting RNA (piRNA), small interfering RNA (siRNA), tRNA-derived small RNA (tsRNA), etc. Current evidence suggest that small RNAs can
-
A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-16 Jiaqi Liu, Haibin Chen, Yalun Li, Yanman Fang, Yang Guo, Shuangquan Li, Juan Xu, Ziqi Jia, Jiali Zou, Gang Liu, Hengyi Xu, Tao Wang, Dingyuan Wang, Yiwen Jiang, Yang Wang, Xuejie Tang, Guangdong Qiao, Yeqing Zhou, Lan Bai, Ran Zhou, Can Lu, Hongwei Wen, Jiayi Li, Yansong Huang, Shuo Zhang, Yong Feng, Hongyan Chen, Shouping Xu, Bailin Zhang, Zhihua Liu, Xiang Wang
Early detection is critical for improving the survival of breast cancer (BC) patients. Exhaled breath testing as a non-invasive technique might help to improve BC detection. However, the breath test accuracy for BC diagnosis is unclear. This multi-center cohort study consecutively recruited 5047 women from four areas of China who underwent BC screening. Breath samples were collected through standardized
-
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-14 Fanyi Meng, Siqi Zhang, Juan Xie, Yuan Zhou, Qingling Wu, Binyan Lu, Shixin Zhou, Xiangyu Zhao, Yang Li
The cytotoxicity of NK cells is largely dependent on IgG Fc receptor CD16a, which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and non-cleavable CD16 (hnCD16) is developed and demonstrated a multi-tumor killing potential. However, the hnCD16 receptor activates a single CD16 signal and provides limited tumor suppression. How to exploit the properties of hnCD16 and
-
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-13 Bhawana George, Suraj Konnath George, Wenyu Shi, Abedul Haque, Ping Shi, Ghazaleh Eskandari, Magnus Axelson, Olle Larsson, Ahmed O. Kaseb, Hesham M. Amin
Correction: Journal of Hematology & Oncology (2019) 12:80 https://doi.org/10.1186/s13045-019-0768-8 The original article [1] contains an error in Fig. 4a whereby the figure of one well that belonged to one cell line was used in another cell line. The corrected image can be viewed ahead. George B, George SK, Shi W, et al. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+
-
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-05 Jieyun Xia, Zhenyu Li, Kailin Xu
B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue attributed to variable BCMA expression, BCMA downregulation, and heterogeneity of tumor antigens in MM. Therefore, additional treatment options with novel therapeutic targets are warranted. G protein-coupled
-
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-06-05 Luming Yang, Zhaole Chu, Meng Liu, Qiang Zou, Jinyang Li, Qin Liu, Yazhou Wang, Tao Wang, Junyu Xiang, Bin Wang
Amino acids are basic nutrients for immune cells during organ development, tissue homeostasis, and the immune response. Regarding metabolic reprogramming in the tumor microenvironment, dysregulation of amino acid consumption in immune cells is an important underlying mechanism leading to impaired anti-tumor immunity. Emerging studies have revealed that altered amino acid metabolism is tightly linked
-
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-05-29 Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median
-
Gastric cancer treatment: recent progress and future perspectives J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-05-27 Wen-Long Guan, Ye He, Rui-Hua Xu
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Systemic therapies for GC, including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. For resectable GC, perioperative chemotherapy has become the standard
-
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-05-26 Joe West, Peter Stilwell, Hanhua Liu, Lu Ban, Mary Bythell, Tim Card, Peter Lanyon, Vasanta Nanduri, Judith Rankin, Mark Bishton, Colin Crooks
Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admissions and death certification. We modelled interactions between demographics and comorbidities and estimated one-year survival by calendar year, age group
-
The artificial intelligence and machine learning in lung cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-05-24 Qing Gao, Luyu Yang, Mingjun Lu, Renjing Jin, Huan Ye, Teng Ma
Since the past decades, more lung cancer patients have been experiencing lasting benefits from immunotherapy. It is imperative to accurately and intelligently select appropriate patients for immunotherapy or predict the immunotherapy efficacy. In recent years, machine learning (ML)-based artificial intelligence (AI) was developed in the area of medical-industrial convergence. AI can help model and